Showing results (661-670 of 782) with videos related to
Sort By:
Pageof 79
Nucleic Acid Therapeutics|May 4, 2016
Effects of Repeated Complement Activation Associated with Chronic Treatment of Cynomolgus Monkeys with 2'-O-Methoxyethyl Modified Antisense OligonucleotideLijiang Shen, Jeffrey A Engelhardt, Gene Hung, et al.Circulation|October 10, 1997
Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodelingP Mulder, V Richard, G Derumeaux, et al.Schizophrenia Research|July 12, 2011
Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up studyG Paul Amminger, Lisa P Henry, Susy M Harrigan, et al.ACS Medicinal Chemistry Letters|May 19, 2022
Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design StrategiesSean P Henry, Maria-Elena Liosi, Joseph A Ippolito, et al.The Journal of Pharmacology and Experimental Therapeutics|January 12, 2021
Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry N-Acetyl-galactosamine Conjugate that Targets the Human Transmembrane Protease Serine 6Thomas A Zanardi, Birgit Korbmacher, Laura Boone, et al.Nucleic Acid Therapeutics|November 6, 2019
Impurity Qualification Toxicology Study for a 2'-O-Methoxyethyl-Modified Antisense Inhibitor in MiceTae-Won Kim, Chris Papagiannis, Daniel Capaldi, et al.Nucleic Acid Therapeutics|March 10, 2016
Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug TransportersRosie Z Yu, Mark S Warren, Tanya Watanabe, et al.Journal of Cataract and Refractive Surgery|March 3, 2022
Ophthalmologists' attitudes toward immediate sequential bilateral cataract surgery: Dutch national surveyLindsay S Spekreijse, Claudette A Veldhuizen, Ype P Henry, et al.Molecular Therapy. Nucleic Acids|January 21, 2015
Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modificationsRosie Z Yu, John S Grundy, Scott P Henry, et al.Brain : a Journal of Neurology|December 28, 1999
Ergotamine in the acute treatment of migraine: a review and European consensusP Tfelt-Hansen, P R Saxena, C Dahlöf, et al.Pageof 79